Tuberculosis (TB) is the main reason behind infectious mortality on this planet, affecting primarily creating nations (DC), whereas diabetes (DM) is likely one of the most prevalent persistent illnesses. This evaluation analyzes the truth that diabetes is at the moment an essential threat issue for creating TB, additionally presenting extra sophisticated TB, extra relapses and better mortality.
The DCs and the fourth world of the big cities are these with the best incidence of TB and a rise in DM, which can make it troublesome to manage tuberculosis illness. On the identical time, the COVID-19 pandemic is complicating the administration of each illnesses as a result of issue of entry to manage and remedy and the worsening of socioeconomic inequalities.
It’s vital to determine a bidirectional screening for TB and DM and promote suggestions for the joint administration of each illnesses. The necessity for instructional interventions on pure natural remedies and to suggest the combination of natural medication into present medical techniques is beneficial.
The impression of several types of psychological problems on long-term glycemic and lipid trajectories following newly identified sort 2 diabetes (T2D) stays unknown. We used real-world scientific information in a population-based cohort to fill this data hole.
We discovered that people with new T2D and preexisting character, anxiousness, unipolar despair, or psychotic dysfunction had greater imply HbA1c ranges over Four years following the onset of T2D, whereas no variations had been discovered concerning LDL-C ranges. This information ought to be thought of within the administration of T2D in these susceptible teams.
Experiences of Sufferers on Pure Natural Therapies for Diabetes Mellitus on the Diabetes Clinic in Base Hospital – Matara, Sri Lanka
The prevalence of diabetes mellitus has turn out to be a world public well being problem. Pure natural remedies for sort 2 diabetes mellitus have been broadly utilized in conventional societies however has just lately turn out to be widespread amongst western societies as effectively. The goal of this research was to discover the expertise of sort 2 sufferers with diabetes mellitus who’re at the moment on pure natural remedy.
A qualitative, phenomenological design has been used. Twelve individuals from each women and men, aged between 25 and 75 years, who had been on medical remedy, had been chosen for sampling. In-depth interviews had been performed on the diabetes clinic in a particular hospital in southern Sri Lanka.
The athematic evaluation was performed, and 6 themes had been derived. The vast majority of individuals (75%) had been motivated to make use of pure natural remedies apart from oral glycemic remedy. Experiences have been recognized as probably the most influential elements in the usage of pure natural remedies.
Charges of osteoporosis analysis and administration after main fragility fractures have remained low in recent times. The extent to which this remedy hole impacts sufferers with diabetes is unclear. This research aimed to match the danger of secondary fractures and charges of osteoporosis prognosis and administration after sentinel fractures in sufferers with and with out diabetes.
A propensity score-matched cohort research was performed utilizing the PearlDiver database. Sufferers aged 50 years and older with main fragility fractures of the hip, wrist, backbone, pelvis, humerus, and different places had been recognized.
Charges of secondary fractures, twin radiograph absorptiometry (DXA) scans, charted osteoporosis diagnoses (Worldwide Classification of Ailments, Ninth and Tenth Revisions), and osteoporosis pharmacotherapy inside 2 years had been in contrast for sufferers with and with out diabetes utilizing multivariable logistic regression.
Inhibitory impact of tumor necrosis factor-α on the basolateral Kir4.1/Kir5.1 channels within the thick ascending limb throughout diabetes
Diabetic nephropathy is a significant contributor to the morbidity and mortality of sufferers with diabetes. TNF-α expression is elevated throughout diabetes and is implicated within the pathogenesis of diabetic nephropathy; nonetheless, its underlying molecular mechanisms stay unclear.
The current research aimed to analyze the impact and molecular mechanism of TNF-α on the basolateral inwardly rectifying potassium (Kir)4.1/Kir5.1 channels within the thick ascending limb (TAL) of rat kidneys utilizing western blotting and the patch clamp approach to supply a theoretical foundation for the reason for the lower in kidney concentrating capability throughout diabetes.
The outcomes demonstrated that urinary TNF-α excretion and protein TNF-α expression within the TAL elevated and basolateral Kir4.1/Kir5.1 channel exercise decreased throughout diabetes; nonetheless, diabetic rats exhibited amelioration of Kir4.1/Kir5.1 exercise with a soluble TNF-α antagonist, TNF receptor fusion protein (TNFR:Fc).
These outcomes prompt that TNF-α inhibited the exercise of the basolateral Kir4.1/Kir5.1 channel within the TAL of rat kidneys throughout diabetes. As well as, the protein expression ranges of phospholipase A2 (PLA2) and cyclooxygenase-2 (COX2) elevated in diabetic rats, the results of which deceased following remedy with TNFR:Fc in contrast with the diabetic group.
Moreover, an agonist of PLA2 (melittin) and COX2 manufacturing [prostaglandin E2 (PGE2)] inhibited the basolateral Kir4.1/Kir5.1 channels. Taken collectively, the outcomes of the current research prompt that the inhibitory impact of TNF-α on the basolateral Kir4.1/Kir5.1 channels within the TAL throughout diabetes is mediated by the PLA2/COX2/PGE2 signaling pathway.
Administration of sort 1 diabetes mellitus utilizing open-source automated insulin supply throughout being pregnant: a case collection
Ladies with sort 1 diabetes (T1D) want to attain tight glycemic management throughout being pregnant to be able to keep away from hostile obstetric and perinatal outcomes. Targets for time in vary (TIR) of >70% [63-140 mg/dL], time beneath vary (TBR) of <5 % and time above vary (TAR) of <25% are beneficial.
We report on 4 pregnancies of girls with T1D who determined to make use of open-source automated insulin supply techniques to handle their diabetes. Knowledge was collected retrospectively from the medical data and Nightscout documentation.Besides the primary trimester of case 3, TIR was >70 % all through all pregnancies.
 RRAD 3'UTR GFP Stable Cell Line |
|
TU072380 |
ABM |
1.0 ml |
EUR 1394 |
 Gene Knock-Out HR Targeting Vector [MCS1-EF1?-RFP-T2A-Puro-pA-MCS2] |
|
HR110PA-1 |
SBI |
10 ug |
EUR 1023 |
|
|
 Gene Knock-Out HR Targeting Vector [MCS1-EF1a-GFP-T2A-Puro-pA-MCS2] |
|
HR410PA-1 |
SBI |
10 ug |
EUR 1023 |
|
|
 Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2] |
|
HR510PA-1 |
SBI |
10 ug |
EUR 1023 |
|
|
) TARGATT? Knock-in iPSC Generation (Master Cell Line) |
|
AST-1100 |
Applied StemCell |
1 vial of 1X10^6 cells |
Ask for price |
|
Description: 6 month |
) TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line) |
|
AST-7001 |
Applied StemCell |
1 Kit |
Ask for price |
|
Description: 6 month |
 HEK-293T cells |
|
T0011002 |
Addexbio |
One Frozen vial |
EUR 455 |
) TARGATT? Knock-in CHO Generation Kit (Master Cell Line) |
|
AST-1200 |
Applied StemCell |
1 Kit |
Ask for price |
|
Description: 12 month |
) TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line) |
|
AST-1300 |
Applied StemCell |
1 Kit |
Ask for price |
|
Description: 12 month |
 RRAD antibody |
|
70R-50359 |
Fitzgerald |
100 ul |
EUR 244 |
|
Description: Purified Polyclonal RRAD antibody |
RRAD antibody |
|
70R-5797 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
RRAD antibody |
|
70R-5798 |
Fitzgerald |
50 ug |
EUR 467 |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
 RRAD Antibody |
|
CSB-PA233809- |
Cusabio |
|
EUR 335 |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
RRAD Antibody |
|
CSB-PA233809-100ul |
Cusabio |
100ul |
EUR 316 |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
RRAD Antibody |
|
1-CSB-PA248209 |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
RRAD Antibody |
|
1-CSB-PA003910 |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
RRAD Antibody |
|
1-CSB-PA779820 |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
 RRAD siRNA |
|
20-abx932133 |
Abbexa |
|
|
|
|
RRAD Antibody |
|
37229-100ul |
SAB |
100ul |
EUR 252 |
 293AAV Cell Line |
|
AAV-100 |
Cell Biolabs |
1 vial |
EUR 508 |
|
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area. |
 293AD Cell Line |
|
AD-100 |
Cell Biolabs |
1 vial |
EUR 461 |
|
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area. |
 293RTV Cell Line |
|
RV-100 |
Cell Biolabs |
1 vial |
EUR 508 |
|
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area. |
 293LTV Cell Line |
|
LTV-100 |
Cell Biolabs |
1 vial |
EUR 508 |
|
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area. |
 HEK-293T Telomerase Over-Expressing Cell Pellet |
|
abx069991-1Pellet |
Abbexa |
1 Pellet |
EUR 398 |
|
|
) RRAD sgRNA CRISPR Lentivector set (Human) |
|
K2069901 |
ABM |
3 x 1.0 ug |
EUR 339 |
 Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out |
|
HR100PA-1 |
SBI |
10 ug |
EUR 938 |
|
|
) RRAD Recombinant Protein (Human) |
|
RP095493 |
ABM |
100 ug |
Ask for price |
 Human RRAD shRNA Plasmid |
|
20-abx954199 |
Abbexa |
|
|
|
|
 293/GFP Cell Line |
|
AKR-200 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
 T47D/GFP Cell Line |
|
AKR-208 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
 A549/GFP Cell Line |
|
AKR-209 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
 HeLa/GFP Cell Line |
|
AKR-213 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: HeLa/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
 NIH3T3/GFP Cell Line |
|
AKR-214 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
 Microplate Swing-Out Centrifuge |
|
abx725026-1Unit |
Abbexa |
1 Unit |
EUR 1476 |
|
|
 Clinical Swing-Out Centrifuge |
|
abx725027-1Unit |
Abbexa |
1 Unit |
EUR 1476 |
|
|
 (Target 1)) RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
|
K2069902 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
|
K2069903 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
|
K2069904 |
ABM |
1.0 ug DNA |
EUR 154 |
 RRAD Blocking Peptide |
|
33R-4793 |
Fitzgerald |
100 ug |
EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797 |
RRAD Blocking Peptide |
|
33R-10070 |
Fitzgerald |
100 ug |
EUR 180 |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798 |
RRAD Blocking Peptide |
|
20-abx063234 |
Abbexa |
|
|
|
|
 Polyclonal RRAD Antibody |
|
APR05556G |
Leading Biology |
0.1ml |
EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications: |
 RRAD Conjugated Antibody |
|
C37229 |
SAB |
100ul |
EUR 397 |
 SKOV-3/Luc Cell Line |
|
AKR-232 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
 MCF-7/Luc Cell Line |
|
AKR-234 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
 OVCAR-5/RFP Cell Line |
|
AKR-254 |
Cell Biolabs |
1 vial |
EUR 572 |
|
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
) 293T Transfection Kit (1 mL) |
|
P902 |
101Bio |
- |
Ask for price |
) 293T Transfection Kit (0.2 mL) |
|
P902S |
101Bio |
- |
Ask for price |
293T Transfection Kit (1 mL) |
|
P903 |
101Bio |
- |
Ask for price |
293T Transfection Kit (0.2 mL) |
|
P903S |
101Bio |
- |
Ask for price |
 and Negative Selection (TK) Against Random Integration) Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration |
|
HR720PA-1 |
SBI |
10 µg |
EUR 1145 |
|
|
 (pORF)) RRAD ORF Vector (Human) (pORF) |
|
ORF031832 |
ABM |
1.0 ug DNA |
EUR 405 |
) Rrad sgRNA CRISPR Lentivector set (Rat) |
|
K7052701 |
ABM |
3 x 1.0 ug |
EUR 339 |
) Rrad sgRNA CRISPR Lentivector set (Mouse) |
|
K3480701 |
ABM |
3 x 1.0 ug |
EUR 339 |
 and Negative Selection (TK) Against Random Integration) Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration |
|
HR700PA-1 |
SBI |
10 µg |
EUR 1145 |
|
|
 and Negative Selection (TK) Against Random Integration) Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration |
|
HR710PA-1 |
SBI |
10 µg |
EUR 1145 |
|
|
 Platinum-E Retroviral Packaging Cell Line, Ecotropic |
|
RV-101 |
Cell Biolabs |
1 vial |
EUR 920 |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
 Platinum-A Retroviral Packaging Cell Line, Amphotropic |
|
RV-102 |
Cell Biolabs |
1 vial |
EUR 920 |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
 Platinum-GP Retroviral Packaging Cell Line, Pantropic |
|
RV-103 |
Cell Biolabs |
1 vial |
EUR 920 |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector. |
) RRAD Recombinant Protein (Mouse) |
|
RP169340 |
ABM |
100 ug |
Ask for price |
) RRAD Recombinant Protein (Rat) |
|
RP226925 |
ABM |
100 ug |
Ask for price |
 Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1?-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2] |
|
HR210PA-1 |
SBI |
10 ug |
EUR 1145 |
|
|
 Total Protein - Murine Embryonic Stem Cell Line D3 |
|
CBA-305 |
Cell Biolabs |
500 ?g |
EUR 345 |
Description: - Isolated from mouse ES-D3 cell line
- Presented as 500 µg at 1 mg/mL in NP-40 Solubilization Buffer
|
 (Target 1)) Rrad sgRNA CRISPR Lentivector (Rat) (Target 1) |
|
K7052702 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) Rrad sgRNA CRISPR Lentivector (Rat) (Target 2) |
|
K7052703 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) Rrad sgRNA CRISPR Lentivector (Rat) (Target 3) |
|
K7052704 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 1)) Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|
K3480702 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|
K3480703 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|
K3480704 |
ABM |
1.0 ug DNA |
EUR 154 |
) PinPoint-FC 293T Platform Cell Line for Targeted Gene Insertion (with PinPoint site already placed) |
|
PIN320A-1 |
SBI |
>2x10^5 cells |
EUR 3104 |
|
|
 TARGATT? Knock-in iPSC Genotyping Kit |
|
AST-1102 |
Applied StemCell |
1 Kit |
Ask for price |
|
Description: 12 month |
 (pORF)) Rrad ORF Vector (Rat) (pORF) |
|
ORF075643 |
ABM |
1.0 ug DNA |
EUR 506 |
 (pORF)) Rrad ORF Vector (Mouse) (pORF) |
|
ORF056448 |
ABM |
1.0 ug DNA |
EUR 506 |
 (pPB-C-His)) RRAD Protein Vector (Human) (pPB-C-His) |
|
PV127326 |
ABM |
500 ng |
EUR 552 |
 (pPB-N-His)) RRAD Protein Vector (Human) (pPB-N-His) |
|
PV127327 |
ABM |
500 ng |
EUR 552 |
 (pPM-C-HA)) RRAD Protein Vector (Human) (pPM-C-HA) |
|
PV127328 |
ABM |
500 ng |
EUR 552 |
 (pPM-C-His)) RRAD Protein Vector (Human) (pPM-C-His) |
|
PV127329 |
ABM |
500 ng |
EUR 552 |
) RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|
K2069905 |
ABM |
3 x 1.0 ug |
EUR 376 |
 Antibody) Out At First Protein Homolog (OAF) Antibody |
|
abx146027-100ug |
Abbexa |
100 ug |
EUR 391 |
|
|
Out At First Protein Homolog (OAF) Antibody |
|
abx027798-400ul |
Abbexa |
400 ul |
EUR 523 |
|
|
Out At First Protein Homolog (OAF) Antibody |
|
abx027798-80l |
Abbexa |
80 µl |
EUR 286 |
|
|
 TARGATT? Knock-in iPSC Quick Knockin Kit |
|
AST-1101 |
Applied StemCell |
1 Kit |
Ask for price |
|
Description: 12 month |
 Human GTP- binding protein RAD, RRAD ELISA KIT |
|
ELI-35549h |
Lifescience Market |
96 Tests |
EUR 824 |
 ELISA Kit) Human GTP-binding protein RAD (RRAD) ELISA Kit |
|
abx385354-96tests |
Abbexa |
96 tests |
EUR 911 |
|
|
 (Target 1)) RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|
K2069906 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 2)) RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|
K2069907 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 3)) RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|
K2069908 |
ABM |
1.0 ug DNA |
EUR 167 |
 Antibody) GTP-Binding Protein RAD (RRAD) Antibody |
|
abx432011-200ul |
Abbexa |
200 ul |
EUR 384 |
|
|
 Antibody) GTP-binding protein RAD (RRAD) Antibody |
|
20-abx241706 |
Abbexa |
|
|
|
|
GTP-binding protein RAD (RRAD) Antibody |
|
20-abx214509 |
Abbexa |
|
|
|
|
GTP-binding protein RAD (RRAD) Antibody |
|
abx332370-100ul |
Abbexa |
100 ul |
EUR 425 |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|
20-abx324872 |
Abbexa |
|
|
|
|
GTP-Binding Protein RAD (RRAD) Antibody |
|
20-abx008742 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
|
|
 ELISA Kit (CUSTOM)) Human OAF (Out at first protein homolog) ELISA Kit (CUSTOM) |
|
ELI-38218h |
Lifescience Market |
96 Tests |
EUR 824 |
 EtB Out Nucleic Acid Staining Solution20,000 x
RoomTemperature |
|
FYD007-200P |
Yeastern Biotech |
200 Preps, 1 ml |
Ask for price |
, Colorimetric) CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|
CBA-135 |
Cell Biolabs |
96 assays |
EUR 821 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|
CBA-135-5 |
Cell Biolabs |
5 x 96 assays |
EUR 3356 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
, Fluorometric) CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|
CBA-140 |
Cell Biolabs |
96 assays |
EUR 856 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|
CBA-140-5 |
Cell Biolabs |
5 x 96 assays |
EUR 3483 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
) Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|
K7052705 |
ABM |
3 x 1.0 ug |
EUR 376 |
) Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|
K3480705 |
ABM |
3 x 1.0 ug |
EUR 376 |
) StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|
CBA-325 |
Cell Biolabs |
96 assays |
EUR 856 |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|
CBA-325-5 |
Cell Biolabs |
5 x 96 assays |
EUR 3361 |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
 (pPB-C-His)) RRAD Protein Vector (Rat) (pPB-C-His) |
|
PV302570 |
ABM |
500 ng |
EUR 603 |
 (pPB-N-His)) RRAD Protein Vector (Rat) (pPB-N-His) |
|
PV302571 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-HA)) RRAD Protein Vector (Rat) (pPM-C-HA) |
|
PV302572 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-His)) RRAD Protein Vector (Rat) (pPM-C-His) |
|
PV302573 |
ABM |
500 ng |
EUR 603 |
 (pPB-C-His)) RRAD Protein Vector (Mouse) (pPB-C-His) |
|
PV225790 |
ABM |
500 ng |
EUR 603 |
 (pPB-N-His)) RRAD Protein Vector (Mouse) (pPB-N-His) |
|
PV225791 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-HA)) RRAD Protein Vector (Mouse) (pPM-C-HA) |
|
PV225792 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-His)) RRAD Protein Vector (Mouse) (pPM-C-His) |
|
PV225793 |
ABM |
500 ng |
EUR 603 |
 Antibody (internal region)) Polyclonal RRAD (aa36-48) Antibody (internal region) |
|
APG00807G |
Leading Biology |
0.1mg |
EUR 484 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human RRAD (aa36-48) (internal region). This antibody is tested and proven to work in the following applications: |
, Colorimetric, Trial Size) CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size |
|
CBA-135-T |
Cell Biolabs |
24 assays |
EUR 432 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
 Chicken Out at first protein homolog, oaf ELISA KIT |
|
ELI-13285c |
Lifescience Market |
96 Tests |
EUR 928 |
 Rat Out at first protein homolog, Oaf ELISA KIT |
|
ELI-15146r |
Lifescience Market |
96 Tests |
EUR 886 |
 ROTOR, 6 X 5ML SWING-OUT ROTOR,1/CS |
|
480138 |
CORNING |
1/pk |
EUR 538 |
|
Description: Lab Equipment; General Purpose Centrifuges (affliated brand) |
 ELISA Kit) Mouse Out at first protein homolog (OAF) ELISA Kit |
|
abx390101-96tests |
Abbexa |
96 tests |
EUR 911 |
|
|
 ELISA Kit) Rat Out at first protein homolog (OAF) ELISA Kit |
|
abx391739-96tests |
Abbexa |
96 tests |
EUR 911 |
|
|
 PIPET CONTROLLER - UNIVERSAL POWER SUPPLY IN:100-250V, OUT: |
|
357489 |
CORNING |
1/pk |
EUR 58 |
|
Description: Falcon Liquid Handling Equipment; Falcon Pipet Controllers and Accessories |
, Trial Size) CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size |
|
CBA-140-T |
Cell Biolabs |
24 assays |
EUR 456 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
 Collagen-based Cell Contraction Assay |
|
CBA-201 |
Cell Biolabs |
24 assays |
EUR 485 |
|
Description: Cell Biolabs? Collagen-based Contraction Assay Kit provides a simple system to assess cell contractivity in vitro and screen cell contraction mediators. Each kit provides sufficient quantities to perform up to 24 assays in a 24-well plate. The kit can be also used in culturing cells in 3D collagen matrix. |
Two caesarean sections had been required; two ladies had a vaginal supply. Beginning weight was regular (2), small (1) and huge (1) for gestational age. We noticed wonderful glycemic management when utilizing open-source automated insulin supply in 4 T1D pregnancies.
 antibody)
